Pegylated Liposomal Doxorubicin Hydrochloride

Phase 1

Pegylated Liposomal Doxorubicin Hydrochloride is one of 9 therapeutic programs targeting Fallopian Tube High Grade Serous Adenocarcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Fallopian Tube High Grade Serous AdenocarcinomaActive, not recruiting

Metastatic Dedifferentiated LiposarcomaRecruiting

Endometrioid AdenocarcinomaActive, not recruiting

Ovarian Serous TumorCompleted

Fallopian Tube High Grade Serous AdenocarcinomaPreclinical

Active, not recruiting

Metastatic Dedifferentiated LiposarcomaPhase 1

Recruiting

Endometrioid AdenocarcinomaPhase 1

Active, not recruiting

Ovarian Serous TumorPreclinical

Completed

Competition

Competitive Landscape

4 competitors in Ovarian Serous Tumor

#DrugCompanyPhaseTrials

Taxol

Teva

Preclinical

1 2

Femara

Novartis

Preclinical

1 3

Hycamtin

MMeitheal

Preclinical

1 4

Pegylated Liposomal Doxorubicin Hydrochloride

NNational Cancer Institute (NCI)

Phase 1

1 5

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Metastatic Dedifferentiated Liposarcoma

NCT05711615

Q1 2027

Phase 3Active, not recruiting

Fallopian Tube Clear Cell Adenocarcinoma

NCT02446600

PreclinicalActive, not recruiting

Fallopian Tube Clear Cell Adenocarcinoma

NCT02502266

Q2 2027

PreclinicalActive, not recruiting

Fallopian Tube High Grade Serous Adenocarcinoma

NCT02839707

Phase 2Recruiting

Locally Advanced Malignant Solid Neoplasm

NCT03907475

Phase 1Active, not recruiting

Endometrioid Adenocarcinoma

NCT04092270

Clinical

Trials by Indication[1]

Fallopian Tube Clear Cell Adenocarcinoma2 trials

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02446600·579 enrolled

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT02502266·582 enrolled

Locally Advanced Malignant Solid Neoplasm1 trial

DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03907475·115 enrolled

Metastatic Dedifferentiated Liposarcoma1 trial

A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05711615·30 enrolled

Fallopian Tube High Grade Serous Adenocarcinoma1 trial

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT02839707·444 enrolled

Ovarian Serous Tumor1 trial

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Preclinical·NCT02101788·260 enrolled

4 more indications

Fallopian Tube Mucinous Adenocarcinoma1 trial

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04739800·120 enrolled

Advanced Malignant Neoplasm1 trial

A Phase I Study of the NovoTTF-100L(P) System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT03203525·38 enrolled

Endometrioid Adenocarcinoma1 trial

A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04092270·55 enrolled

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma1 trial

A Randomized Phase II Trial of Sacituzumab Govitecan (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor Therapy

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07504588·87 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Pegylated Liposomal Doxorubicin Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Pegylated Liposomal Doxorubicin Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

Pegylated Liposomal Doxorubicin Hydrochloride

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Fallopian Tube Clear Cell Adenocarcinoma2 trials

Locally Advanced Malignant Solid Neoplasm1 trial

Metastatic Dedifferentiated Liposarcoma1 trial

Fallopian Tube High Grade Serous Adenocarcinoma1 trial

Ovarian Serous Tumor1 trial

Fallopian Tube Mucinous Adenocarcinoma1 trial

Advanced Malignant Neoplasm1 trial

Endometrioid Adenocarcinoma1 trial

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News